Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Recurrence 2Myelodysplastic Syndromes 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Stomach Neoplasms 1Prostatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia 1Breast Neoplasms 1

Interventions

Cyclophosphamide 24Mycophenolic Acid 15fludarabine phosphate 14fludarabine 13Whole-Body Irradiation 13Tacrolimus 12Rituximab 12Melphalan 12Filgrastim 11Cyclosporine 11Busulfan 11Radiotherapy 10Peripheral Blood Stem Cell Transplantation 10Antilymphocyte Serum 10Methotrexate 9Doxorubicin 9Gemcitabine 8Etoposide 8Brentuximab Vedotin 8Sirolimus 7pembrolizumab 6Vinblastine 6Nivolumab 6Methylprednisolone 6Granulocyte Colony-Stimulating Factor 6Alemtuzumab 6Dacarbazine 5Cytarabine 5Cord Blood Stem Cell Transplantation 5Carmustine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Hodgkin Disease × mocetinostat × Clear all
NCT00358982 2015-07-03

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Mirati Therapeutics Inc.

Phase 2 Terminated
51 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT00543582 2015-07-01

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Mirati Therapeutics Inc.

Phase 2 Terminated
23 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡